Nivolumab: A Review in Advanced Melanoma Topical Collection on Immuno-Oncology

Drugs

Volumn 75, Issue 12, 2015, Pages 1413-1424

  Scott, Lesley J ^a  

^a Mairangi Bay   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; B RAF KINASE; BILIRUBIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER STAGING; COLITIS; CONCENTRATION AT STEADY-STATE; DIABETES MELLITUS; DIARRHEA; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOLITIS; ERYTHEMA; FATIGUE; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNOSURVEILLANCE; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LEUKOCYTE COUNT; MACULOPAPULAR RASH; MELANOMA; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; THROMBOCYTOPENIA; VITILIGO; VOLUME OF DISTRIBUTION; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECTS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; MELANOMA; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84939263031     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0442-6     Document Type: Article

References (46)

1. Johnson KM, Mcpherson E, Oseneko K, et al. Cost-effectiveness of therapies for melanoma. Expert Rev Pharmacoecon Outcomes Res. 2015;15(2):229-42.
2. Fox MC, Lao CD, Schwartz JL, et al. Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologists. Part II: management of stage IV disease. J Am Acad Dermatol. 2013;68:13.e1-13.
3. Fox MC, Lao CD, Schwartz JL, et al. Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist. Part I: management of stage III disease. J Am Acad Dermatol. 2013;68:1.e-9.
4. Dummer R, Hauschild A, Guggenheim M, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii86-91.
5. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
6. Luke JJ, Ott P. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479-92.
7. Hall RD, Kudchadkar RR. BRAF mutations: signalling, epidemiology, and clinical experience in multiple malignancies. Cancer Control. 2014;21(3):221-30.
8. Giovanni P, Giovanni P, Aldo T, et al. Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT and GNAQ melanomas. Dis Markers. 2014;2014:671283.
9. Sullivan R, LoRosso P, Boerner S, et al. Achievements and challenges of molecular targeted therapy in melanoma. Am Soc Clin Oncol Educ Book. 2015;35:177-86.
10. Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res. 2014;20(24):6258-68.
11. Shih K, Arkenau HT, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs. 2014;74(17):1993-2013.
12. Tsai KK, Daud AL. The role of anti-PD-1/PD-L1 agents in melanoma: progress to date. Drugs. 2015. doi: 10.1007/s40265-015-0376-z.
13. Saranga-Perry V, Ambe C, Zager JS, et al. Recent developments in the medical and surgical treatment of melanoma. CA Cancer J Clin Oncol. 2014;64:171-85.
14. Deeks ED. Nivolumab: a review of its use in patients with malignant melanoma. Drugs. 2014;74(11):1233-9.
15. Berman D, Korman A, Peck R, et al. The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. Pharmacol Ther. 2015;148:132-53.
16. Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846-56.
17. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064-74.
18. Das R, Verma R, Sznol M, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015;194(3):950-9.
19. Urba WJ, Martín-Algarra S, Callahan M, et al. Immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma [abstract no. 2855]. In: 106th American Association for Cancer Research Annual Meeting; 2015.
20. Agrawal S, Roy A, Feng Y, et al. Immunogenicity of nivolumab and its impact on pharmacokinetics and safety in subjects with metastatic solid tumors [abstract no. 115]. In: American Society for Clinical Pharmacology and Therapeutics Annual Meeting; 2015.
21. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54.
22. Weber J, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 therapy (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375-84.
23. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-30.
24. Agrawal S, Williams D, Waxman I, et al. Absence of QT prolongation effect by nivolumab or ipilimumab in patients with solid tumors [abstract no. 117]. In: American Society for Clinical Pharmacology and Therapeutics Annual Meeting; 2015.
25. Feng Y, Bajaj G, Wang X, et al. Model-based analysis of nivolumab to support clinical pharmacology profiling in subjects with solid tumors [abstract]. Clin Pharmacol Ther. 2015;97(Suppl 1):S41-2.
26. Bristol-Myers Squibb Company. Opdivo (nivolumab) injection, for intravenous use: US prescribing information 2015. http://www.fda.gov/. Accessed 26 Mar 2015.
27. European Medicines Agency. Opdivo 10 mg/mL concentrate for infusion: summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 1 July 2015.
28. Passey C, Simon J, Roy A, et al. Assessment of drug interaction potential by nivolumab using cytokine modulation data [abstract no. 118]. In: American Society for Clinical Pharmacology and Therapeutics Annual Meeting; 2015.
29. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020-30.
30. Hodi FS, Sznol M, Kluger HM, et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial [abstract no. 9002]. J Clin Oncol. 2014;32(15 Suppl 1).
31. Wang X, Gaurav B, Feng Y, et al. Characterization of exposure-response relationship for nivolumab in subjects with advanced melanoma progressing post anti-CTLA4 [abstract no. 73]. In: American Society for Clinical Pharmacology and Therapeutics Annual Meeting; 2015.
32. Yamamoto N, Nokihara H, Yamada Y, et al. Phase I study of anti pd-1 antibody ONO-4538 in Japanese patients with advanced solid tumors [abstract no. IS6-3]. Ann Oncol. 2012;23(Suppl 11)(8):xi26-8.
33. Kiyohara Y, Tahara H, Uhara H, et al. Long-term survival of patients with advanced melanoma in phase 2 study of nivolumab (ANTI-PD-1; ONO-4538/BMS-936558) [abstract no. 1096P]. Ann Oncol. 2014;25(Suppl 4):iv379-80.
34. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-33.
35. Kluger HM, Sznol M, Callahan MK, et al. Survival, response duration, and activity by BRAF mutation status in a phase 1 trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab concurrent therapy in advanced melanoma (MEL) [abstract]. Pigment Cell Melanoma Res. 2014;27(6):1203. Plus oral presentation at Society for Melanoma Research 2014 Congress.
36. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006-17.
37. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilumumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):21-34.
38. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Efficacy and safety results from a phase III trial of nivolumab alone or combined with ipilimumab vs. ipilimumab alone in treatment-naive patients with advanced melanoma (CheckMate 067) [abstract no. LBA1 plus oral presentation]. In: 2015 ASCO Annual Meeting; 2015.
39. Weber JS, Antonia SJ, Topalian S, et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis [poster 9018 plus oral presentation]. In: 2015 ASCO Annual Meeting; 2015.
40. ®): melanoma version 3.2015. 2015. http://www.nccn.org/patients. Accessed 18 June 2015.
41. Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ Book. 2012;174-7.
42. US FDA. Nivolumab. 2014. http://www.fda.gov/. Accessed 11 May 2015.
43. Bristol-Myers Squibb Company. U.S. Food and Drug Administration accepts supplemental Biologics License Application for Opdivo (nivolumab) in patients with previously untreated advanced melanoma. 2015. http://news.bms.com/. Accessed 29 Apr 2015.
44. PharmaTimes. FDA priority review for Opdivo/Yervoy combo in skin cancer. 2015. http://www.pharmatimes.com/. Accessed 4 June 2014.
45. European Medicines Agency. Summary of opinion (initial authorization): nivolumab BMS. 2015. http://www.ema.europa.eu/. Accessed 23 July 2015.
46. Hodi FS, Baudelet C, Chen AC. An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL) [abstract no. TPS9107]. J Clin Oncol. 2013;31(Suppl).